KORTUC Launches Global Cervical Cancer Study, Expanding Pipeline to Second IndicationLed by the University of California San Diego, the clinical trial evaluates the safety and efficacy of KRC-01, a radiosensitizer designed to make solid tumors more susceptible to radiation, under a study protocol reviewed by the U.S. Food and Drug Administration
KORTUC Inc. Closed Financing From AXA Japan to Accelerate Pivotal Phase II Study of Novel Radiosensitizer for Cancer Radiotherapy
Today KORTUC Inc., a Japanese clinical-stage biopharmaceutical company focusing on the clinical and product development of a novel radiosensitizer improving the effectiveness of cancer radiotherapy (RT), announces the closing of an equity investment from AXA Japan.
